Bioventus (BVS) Asset Writedowns and Impairment (2020 - 2026)

Bioventus (BVS) has reported Asset Writedowns and Impairment for 7 consecutive years, with -$85000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Asset Writedowns and Impairment fell 144.04% year-over-year to -$85000.0; the trailing twelve-month figure through Jun 2026 stood at $558000.0 (down 89.53% YoY), and the FY2025 full-year result was $1.3 million, down 96.55% from the prior year.
• Asset Writedowns and Impairment fell to -$85000.0 in Q2 2026 per BVS's latest filing, from $230000.0 in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $124.7 million in Q4 2022 and bottomed at -$1.3 million in Q3 2023.
• Historically, Asset Writedowns and Impairment has averaged $14.8 million across 5 years, with a median of $650000.0 in 2025.
• The sharpest annual moves came in 2022 and 2026: Asset Writedowns and Impairment soared 56323.98% in 2022, then plunged 144.04% in 2026.
• Over 5 years, Asset Writedowns and Impairment stood at $10.3 million in 2022, then plunged by 112.98% to -$1.3 million in 2023, then soared by 283.97% to $2.5 million in 2024, then tumbled by 87.3% to $312000.0 in 2025, then sank by 127.24% to -$85000.0 in 2026.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered -$85000.0, $230000.0, and $312000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.